P. Murali Doraiswamy

P. Murali Doraiswamy

Professor of Psychiatry and Behavioral Sciences

External Address: 
3550 Hosp South, Durham, NC 27710
Internal Office Address: 
DUMC - 3018, Durham, NC 27710

Overview

Murali Doraiswamy is a doctor and translational scientist at Duke University where he directs a clinical trials unit developing novel technologies and treatments for enhancing brain health.  He has served as an advisor to leading businesses, government agencies and patient advocacy groups. 

Murali has been a health advisor for Men's Health magazine and AARP Magazine, and is a co-author of a popular book, The Alzheimer's Action Plan.  His research has been featured in media outlets such as The New York Times, Oprah, Dr Oz Show, CBS Morning, Discovery, BBC, USA Today, NPR, and BBC.   

Dr. Doraiswamy is a member of the World Economic Forum's Global Future Councils.    

  

Education & Training

  • M.B.B.S., University of Madras (India) 1987

Selected Grants

Racial and Geographic Disparities in Risk and Survival of Alzheimer's Disease and Related Dementias awarded by National Institutes of Health (Senior Investigator). 2019 to 2024

Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-AD awarded by National Institutes of Health (Co Investigator). 2018 to 2023

Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-AD awarded by National Institutes of Health (Co Investigator). 2018 to 2023

Gut Liver Brain Biochemical Axis in Alzheimer's Disease awarded by National Institutes of Health (Co Investigator). 2018 to 2023

Metabolic Networks and Pathways Predictive of Sex Differences in AD Risk and Responsiveness to Treatment awarded by National Institutes of Health (Co Investigator). 2018 to 2023

Predicting prebiotic effects on human microbiota, behavior, and cognition. awarded by Office of Naval Research (Collaborator). 2018 to 2021

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) awarded by University of Southern California (Principal Investigator). 2016 to 2020

Metabolic Network Analysis of Biochemical Trajectories in Alzheimer's Disease awarded by National Institutes of Health (Co Investigator). 2017 to 2020

Pages

Goudey, Benjamin, et al. “A blood-based signature of cerebrospinal fluid Aβ1-42 status..” Sci Rep, vol. 9, no. 1, Mar. 2019. Pubmed, doi:10.1038/s41598-018-37149-7. Full Text

Nho, Kwangsik, et al. “Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers..” Alzheimers Dement, vol. 15, no. 2, Feb. 2019, pp. 232–44. Pubmed, doi:10.1016/j.jalz.2018.08.012. Full Text

Petrella, Jeffrey R., et al. “Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer's Disease..” Comput Math Methods Med, vol. 2019, 2019. Pubmed, doi:10.1155/2019/6216530. Full Text

MahmoudianDehkordi, Siamak, et al. “Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome..” Alzheimers Dement, vol. 15, no. 1, Jan. 2019, pp. 76–92. Pubmed, doi:10.1016/j.jalz.2018.07.217. Full Text Open Access Copy

Sohn, Dongwha, et al. “Sex Differences in Cognitive Decline in Subjects with High Likelihood of Mild Cognitive Impairment due to Alzheimer's disease..” Sci Rep, vol. 8, no. 1, May 2018. Pubmed, doi:10.1038/s41598-018-25377-w. Full Text

Lu, Donghuan, et al. “Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer's Disease using structural MR and FDG-PET images..” Sci Rep, vol. 8, no. 1, Apr. 2018. Pubmed, doi:10.1038/s41598-018-22871-z. Full Text

Mills, Paul J., et al. “Change in Sense of Nondual Awareness and Spiritual Awakening in Response to a Multidimensional Well-Being Program..” J Altern Complement Med, vol. 24, no. 4, Apr. 2018, pp. 343–51. Pubmed, doi:10.1089/acm.2017.0160. Full Text

Mahjoub, Ines, et al. “Brain multiplexes reveal morphological connectional biomarkers fingerprinting late brain dementia states..” Sci Rep, vol. 8, no. 1, Mar. 2018. Pubmed, doi:10.1038/s41598-018-21568-7. Full Text

Privitera, Gregory J., et al. “No calorie comfort: Viewing and drawing "comfort foods" similarly augment positive mood for those with depression..” J Health Psychol, vol. 23, no. 4, Mar. 2018, pp. 598–607. Pubmed, doi:10.1177/1359105316681861. Full Text

Varma, Vijay R., et al. “Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study..” Plos Med, vol. 15, no. 1, Jan. 2018. Pubmed, doi:10.1371/journal.pmed.1002482. Full Text

Pages

Harenberg, S., et al. “Knowledge-guided maximal clique enumeration.” Lecture Notes in Computer Science (Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), vol. 10086 LNAI, 2016, pp. 604–18. Scopus, doi:10.1007/978-3-319-49586-6_43. Full Text

Doraiswamy, P. Murali, et al. “Preimplantation Genetic Diagnosis (PGD) for Familial Alzheimer's Disease Due To PSEN1 Mutation.” Annals of Neurology, vol. 76, WILEY-BLACKWELL, 2014, pp. S90–S90.

Hochstetler, Helen, et al. “Relationship of Florbetapir F18 PET Amyloid Plaque Neuroimaging with Future Cognitive Decline over 36 Months.” The American Journal of Geriatric Psychiatry, vol. 21, no. 3, Elsevier BV, 2013, pp. S136–S136. Crossref, doi:10.1016/j.jagp.2012.12.180. Full Text

Witte, Michael, et al. “Florbetapir PET Imaging Predicts Postmortem Amyloid Burden in Alzheimer's Disease Despite Presence of Other Neuropathologies.” The American Journal of Geriatric Psychiatry, vol. 21, no. 3, Elsevier BV, 2013, pp. S138–39. Crossref, doi:10.1016/j.jagp.2012.12.183. Full Text

Sheldon, F. C., et al. “Disruption of Functional Brain Connections in Alzheimer's Disease.” Journal of Nuclear Medicine, vol. 51, no. 5, SOC NUCLEAR MEDICINE INC, 2010, pp. 828–29.

Doraiswamy, P. Murali, et al. “Atypical antipsychotic drugs and diabetes mellitus in the USFDA adverse event reporting system (AERS) database in pediatric and adult patients.” Biological Psychiatry, vol. 63, no. 7, ELSEVIER SCIENCE INC, 2008, pp. 283S-284S.

Kaddurah-Daouk, Rima, et al. “Metabolomic mapping of schizophrenia and atypical antipsychotic effects.” Biological Psychiatry, vol. 61, no. 8, ELSEVIER SCIENCE INC, 2007, pp. 164S-164S.

Szarfman, A., et al. “Risperidone and pituitary tumors: a pharmacovigilance study.” Bipolar Disorders, vol. 7, BLACKWELL PUBLISHING, 2005, pp. 116–17.

Pomara, N., et al. “Elevated plasma A beta(1-42) in geriatric depression.” Biological Psychiatry, vol. 57, no. 8, ELSEVIER SCIENCE INC, 2005, pp. 200S-200S.

Pages